Modality
Vaccine
MOA
SOS1i
Target
IL-23
Pathway
Sphingolipid
Pancreatic CaNSCLCNASH
Development Pipeline
Preclinical
Feb 2017
→ Sep 2029
PreclinicalCurrent
NCT05406044
38 pts·NASH
2017-02→2029-09·Terminated
38 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-093.4y awayInterim· NASH
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2029-09-09 · 3.4y away
NASH
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05406044 | Preclinical | NASH | Terminated | 38 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |